Zydus Lifesciences gets US FDA nod for seizure drug

Lacosamide is indicated to treat partial-onset seizures

The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad

Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg had annual sales of $249 mn in the United States, as per IQVIA data